Clinical Trial Search

Primary: Change in Age-Adjusted Scores at Week Six From Baseline in the Attention Task of the CogState Battery — -0.16; 0.14 Z Score

Primary: Number of Oxycodone Tablets Used Day 1 — 1.0; 1.0 Oxycodone Tablets — p=.87

Primary: Vitamin D Status — 81.6; 5.6 Percentage of participants in study arm

Primary: Stage 2: Change From Baseline in the Average Number of Urinary Incontinence Episodes (UIEs) Per Day — -2.72; -1.62; -0.89; -1.52 episodes per day — p=0.0845

Primary: Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer. — 0; 12; 12; 4 Participants

Primary: Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone. — 5; 11 months

Primary: Progression-free Survival (PFS) as Per RECIST v 1.1 Using Central Assessment - Number of Participants With Progression or Death — 62; 32; 3; 1 Participants

Primary: Efficacy of Combined Treatment With Deferasirox and Deferoxamine Over 12 Months — -6.2 mg/g

Primary: Objective Response Rate (ORR) — 5.3 Percent of participants

Primary: Incidence of Adverse Drug Reaction — 3; 3; 3; 3 Participants

Primary: Clinical Cure (Complete Resolution of Signs and Symptoms) — 9; 14; 13; 14 Participants

Primary: Change in Postsurgical Pain Based on the Weighted Sum of Pain Intensity (SPI) Assessments Over 96 Hours of the NRS Scores = Area Under the Curve (AUC) — 317.09; 321.72…

Primary: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Slope Change — -1.66; -1.24 Change in ALSFRS-R Total Score Per Month — p=0.03

Primary: Inferior Corneal Staining (ICS) Score — 1.8; 1.9 units on a scale

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 3; 6; 6; 5 Participants